广州市香雪制药股份有限公司 公司章程 广州市香雪制药股份有限公司 章 程 （2024 年 5 月修订） 二〇二四年五月 | X | | --- | | 第一章 总 则 2 | | --- | | 第二章 经营宗旨和范围 3 | | 第三章 股 份 3 | | 第一节 股份发行 3 | | 第二节 股份增减和回购 4 | | 第三节 股份的转让 5 | | 第四章 股东和股东大会 7 | | 第一节 股 东 7 | | 第二节 股东大会的一般规定 10 | | 第三节 股东大会的召集 13 | | 第四节 股东大会的提案和通知 14 | | 第五节 股东大会的召开、表决和决议 16 | | 第五章 董事会 23 | | 第一节 董 事 23 | | 第二节 独立董事 26 | | 第三节 董事会 30 | | 第四节 董事会秘书 36 | | 第六章 总经理及其他高级管理人员 38 | | 第七章 监事会 40 | | 第一节 监 事 40 | | 第二节 监事会 41 | | 第三节 监事会决议 42 | | 第八章 劳动人事制度 43 | | 第九章 利润分配 43 | | 第十章 财务会计制度和审计制度 ...

证券代码:300147 证券简称: 香雪制药 公告编号:2024-026 广州市香雪制药股份有限公司 关于改选董事、改聘高级管理人员及证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）第九届董事会第十九次 会议审议通过了《关于改选第九届董事会非独立董事的议案》《关于改聘财务总 监的议案》《关于改聘证券事务代表的议案》，具体情况如下： 一、董事、高级管理人员及证券事务代表变动情况 （一）董事变动 公司董事会于近日收到董事陈文进先生的辞呈，其申请辞去公司第九届董事 会非独立董事职务和薪酬与考核委员会委员职务，原定任期至公司第九届董事会 届满之日止。根据《公司法》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》《公司章程》的相关规定，陈文进先生不担任董事， 不会导致公司董事会人数低于法定最低人数，亦不会影响董事会正常运作和公司 正常的生产经营。 截至本公告披露日，陈文进先生直接持有公司股票 60,000 股，为经公司 2023 年第一次临时股东大会审议通过的应回购注销的 20 ...

广州市香雪制药股份有限公司 章程修订对照表 广州市香雪制药股份有限公司（以下简称"公司"）第九届董事会第十九次 会议审议通过了《关于修订及制订部分制度的议案》，同意公司《中华人民共和 国公司法》《中华人民共和国证券法》《上市公司章程指引》《上市公司独立董 事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上公司 自律监管指引第 2 号——创业板上市公司规范运作》《上市公司股份回购规则》 等相关法律、法规及规范性文件的规定，结合公司实际情况，对《公司章程》部 分条款做出修订。具体修订内容如下： | 修订前 | 修订后 | | --- | --- | | 第二十一条 公司根据经营发展的需要，依照法律、法规 | 第二十一条 公司根据经营发展的需要，依照法律、法规 | | 的规定，经股东大会决议，可以采用下列方式增加股本： | 的规定，经股东大会决议，可以采用下列方式增加资本： | | （一） 向社会公众发行股份； | （一）公开发行股份； | | 、、、、、、 | （二）非公开发行股份； | | （五） 法律、行政法规规定以及中国证监会批准的其他方 | （三）向现有股东派送红股； | | 式。 | （ ...

（以下简称《证券法》）、《上市公司治理准则》（以下简称《治理准则》）、《上市 公司独立董事管理办法》（以下简称《管理办法》）、《深圳证券交易所创业板股票 上市规则》（以下简称"《上市规则》"）、《广州市香雪制药股份有限公司章程》（以 下简称"《公司章程》"）及其他有关规定，公司设立董事会薪酬与考核委员会， 并制订本细则。 第二条 薪酬与考核委员会是董事会设立的专门工作机构，主要负责制订 公司董事、总经理及其他高级管理人员的考核标准；负责制订、审查公司董事、 监事、总经理及其他高级管理人员的薪酬方案，对董事会负责。 第三条 本细则所称董事、监事是指在公司领取薪酬的董事（含独立董事）、 监事，其他高级管理人员是指公司的副总经理、董事会秘书、财务总监及董事会 任命的其他高级管理人员 广州市香雪制药股份有限公司 董事会薪酬与考核委员会工作细则 第一章 总则 第一条 为进一步建立健全广州市香雪制药股份有限公司（以下简称"公 司"）董事、监事及高级管理人员的考核和薪酬管理制度，完善公司治理结构， 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》 第二章 委员会组成 第四条 薪酬与考核委员会成员 ...

广州市香雪制药股份有限公司 董事会议事规则 第一章 总 则 第一条 为进一步明确广州市香雪制药股份有限公司（以下简称"公司"） 董事会的职权范围，规范董事会议事和决策行为，确保董事会的工作效率和科 学决策，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）《上市公司治理准则》《创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规 范运作》等有关法律、行政法规、规范性文件以及《广州市香雪制药股份有限 公司章程》（以下简称"公司章程"）的规定制定本规则。 第二章 董 事 第二条 董事应具备以下任职资格： 1、公司董事为自然人； 2、具有公司运作的基本知识，熟悉国家的经济政策以及有关法律、法规， 具有与担任董事相适应的能力和经验； （四）担任因违法被吊销营业执照的公司、企业的法定代表人，并负有个人 3、不存在本规则第三条规定的情形。 4、董事应保证有足够的时间和精力履行其应尽的职责； 第三条 有下列情形之一者，不得担任公司的董事： （一）无民事行为能力或者限制民事行为能力； （二）因犯有贪污、贿赂、侵占财产、挪用财产罪或者破坏 ...

第一条 为保证公司持续、规范、健康地发展，进一步完善公司治理结构， 加强董事会决策科学性，根据《中华人民共和国公司法》（以下简称《公司法》）、 广州市香雪股份有限公司 董事会审计委员会工作细则 第一章 总 则 《中华人民共和国证券法》（以下简称《证券法》）、《上市公司治理准则》（以下 简称《治理准则》）、《上市公司独立董事管理办法》（以下简称《管理办法》）、《深 圳证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、《广州市香雪制 药股份有限公司章程》（以下简称"《公司章程》"）及其他有关规定，公司设立董 事会审计委员会，并制定本细则。 第二条 董事会审计委员会是董事会下设的专门委员会，对董事会负责、向 董事会报告工作。主要负责审核公司财务信息及其披露、监督及评估内外部审计 工作和内部控制。 第二章 委员会组成 第三条 审计委员会成员由三名不在公司担任高级管理人员的董事组成，独 立董事人数应当过半，其中至少一名独立董事为专业会计人士。 第四条 审计委员会委员由董事长、过半数独立董事或者全体董事的三分之 一提名，并由全体董事的过半数选举产生和罢免。 第五条 审计委员会设主任委员（召集人）一名，由独立董事 ...

第一章 总则 第一条 为了规范广州市香雪制药股份有限公司（以下简称"公司"）选聘 （含续聘、改聘，下同）会计师事务所行为，提高财务信息质量，切实维护股东 利益，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《中华人民共和国会计法》（以下简称"会 计法"）《国有企业、上市公司选聘会计师事务所管理办法》（以下简称"《选聘办 法》"）等法律、法规及《广州市香雪制药股份有限公司章程》（以下简称"《公司 章程》"）的规定，结合公司实际情况，特制定本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规的要求， 聘任会计师事务所对财务会计报告发表审计意见、出具审计报告的行为。公司聘 任会计师事务所从事除财务会计报告审计之外的其他法定审计业务的，可以比照 本制度执行。 第三条 公司聘用或解聘会计师事务所，应当由董事会审计委员会（以下简 称"审计委员会"）审议同意后，提交董事会审议，并由股东大会决定。公司不 得在董事会、股东大会审议批准前聘请会计师事务所开展审计业务。 广州市香雪制药股份有限公司 会计师事务所选聘制度 （五）认真执行有关财务审计的法 ...

深 圳 证 券 交 易 所 关于对广州市香雪制药股份有限公司的 年报问询函 创业板年报问询函〔2024〕第 112 号 广州市香雪制药股份有限公司董事会 ： 2024 年 4 月 30 日，你公司披露 2023 年度报告，审计意 见为保留意见，主要因会计师无法对部分固定资产和在建工 程余额的准确性获取充分、适当的审计证据，也无法确定是 否存在与之相关的关联方资金占用情形。同日披露的《关于 前期会计差错更正及追溯调整的公告》显示，公司对 2021 年年初数、2021 年度、2022 年度财务报表及 2023 年 1-3 季 报中涉及生物岛相关的在建工程、固定资产、其他应收款、 其他应付款等报表项目进行了差错更正，追溯调整后，不会 导致公司已披露的 2021 年度、2022 年度财务报表出现盈亏 性质的改变。请你公司补充说明以下事项： 1.2021 年 4 月，控股股东广州市昆仑投资有限公司（以 下简称"昆仑投资"）将广州香岚健康产业有限公司（以下 简称"协和精准"）100%股权转让给公司；在协和精准转让 1 给公司之前，协和精准在建工程部分中有 5.91 亿元、以及 与此款项相关的以及土地价值为依据计提的 1. ...

Financial Performance - The company's consolidated revenue for 2023 was RMB 2,299.29 million, representing a year-on-year increase of 5.13%[4] - The core traditional Chinese medicine segment saw revenue growth exceeding 100%[4] - The net loss attributable to shareholders was RMB -388.96 million, but this showed a year-on-year improvement of 26.62%[4] - Financial expenses amounted to RMB 241.47 million, significantly impacting profitability[4] - The company's operating revenue for 2023 was ¥2,299,287,682.53, representing a 5.13% increase compared to ¥2,187,069,901.40 in 2022[25] - The net profit attributable to shareholders for 2023 was ¥388,963,842.58, a decrease of 26.62% from ¥533,158,456.93 in 2022[25] - The net cash flow from operating activities increased by 15.86% to ¥263,441,902.31 in 2023, compared to ¥227,377,262.86 in 2022[25] - The total assets at the end of 2023 were ¥8,280,629,970.00, a decrease of 4.18% from ¥9,353,000,530.00 at the end of 2022[25] - The net assets attributable to shareholders decreased by 16.56% to ¥1,924,701,820.00 at the end of 2023, down from ¥2,405,133,050.00 at the end of 2022[25] - The company reported a basic and diluted earnings per share of -0.59 in 2023, an improvement of 26.25% from -0.81 in 2022[25] Asset Management - The company recognized asset impairment losses of RMB 163.34 million across various asset categories[4] - The total assets of the company were CNY 828,063.00 million, a decrease of 4.18% from the beginning of the period[59] - The company's accounts receivable at the end of the reporting period amounted to CNY 768.40 million, with a low risk of bad debts due to its cash-on-delivery policy for most distributors[115] - The company has fixed assets valued at CNY 3,369.35 million and construction in progress of CNY 1,214.43 million, which may lead to high depreciation costs and potential underperformance of expected returns[117] Research and Development - The company is conducting clinical trials for new drugs, including TAEST16001 for synovial sarcoma in Phase II and TAEST1901 for primary liver cancer, which will start Phase I trials[50] - The company has established a complete TCR-T technology platform for tumor-specific antigen discovery and TCR screening, enhancing its R&D capabilities[51] - The company is currently conducting research and development on oral paclitaxel in collaboration with ATHENEX, INC., which has not yet received FDA approval[111] - R&D investment amounted to ¥123,323,635.20 in 2023, a decrease of 7.67% from ¥133,932,747.77 in 2022, with the R&D expense as a percentage of revenue dropping to 5.36% from 6.12%[82] - The company plans to increase R&D efforts in TCR-T cell immunotherapy technology and collaborate with renowned research institutions[106] Market Strategy - The company is focusing on optimizing internal management and expanding into markets outside the province to mitigate market environment impacts[4] - The company expanded its marketing efforts, conducting 500 events under the "Spark Plan" and entering 30 provincial markets nationwide[60] - The company aims to develop a comprehensive health industry chain, integrating TCM cultivation, production, and distribution[44] - The company plans to raise up to ¥95,988.40 million through a private placement to fund projects including the Meizhou Wuhua Industrial Park and digital platform upgrades[64] - The company is exploring partnerships with technology firms to enhance its digital health services, aiming for a 15% increase in user engagement[151] Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation and protection of shareholder interests[125] - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with regulatory requirements[127] - The company has maintained compliance with corporate governance standards and ensured the protection of shareholders' rights[166] - The company has faced multiple warnings from the China Securities Regulatory Commission regarding non-compliance with information disclosure regulations[154] - The company has been under scrutiny for the actions of its chairman and board secretary, receiving warnings in 2019, 2021, and 2022[155] Environmental Responsibility - The company has established environmental protection measures in compliance with multiple national and local regulations[187] - The company has obtained the necessary environmental impact assessment approvals and pollutant discharge permits for its projects[188] - The wastewater treatment processes at the company’s facilities have consistently met discharge standards, with no exceedances reported[189] - In 2023, the company invested approximately 750,000 yuan in wastewater treatment, environmental monitoring, and solid/hazardous waste management[195] - The company paid an environmental protection tax of 14,300 yuan in 2023[195] Operational Challenges - The company has significant short-term and long-term borrowings, which pose financial risks[6] - The company has faced uncertainties regarding its ability to continue as a going concern, as indicated by the negative net profit figures over the past three years[25] - The company acknowledges the risk of intensified market competition in the traditional Chinese medicine sector, which may affect its sales growth and profitability[110] - The company faces significant operational risks due to industry policy changes, which may adversely affect its business if it fails to adapt its strategies accordingly[107] - The company is facing liquidity constraints impacting investment execution, leading to delays in project funding[93] Future Outlook - Future guidance suggests a revenue target of CNY 2.5 billion for the next fiscal year, indicating a growth expectation of approximately 11%[143] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[149] - The company is committed to digital transformation, aiming to enhance procurement management and optimize the supply chain to improve production efficiency[106] - The company plans to enhance resource integration towards its main business, improve scale efficiency, and accelerate the divestment of non-core assets[106] - The company is exploring potential mergers and acquisitions to enhance its competitive edge in the pharmaceutical sector[144]

Financial Performance - The company's revenue for Q1 2024 was ¥568,856,745.84, a decrease of 3.37% compared to ¥588,724,855.57 in the same period last year[4] - The net profit attributable to shareholders was -¥35,659,979.04, representing a significant decline of 886.00% from a profit of ¥4,536,891.13 in the previous year[4] - The basic earnings per share were -¥0.05, a drop of 600.00% from ¥0.01 in the previous year[4] - Net profit for Q1 2024 was a loss of CNY 28,629,807.17, compared to a profit of CNY 8,281,817.19 in the same period last year[20] - The total comprehensive income for Q1 2024 was a loss of CNY 28,625,879.70, compared to a gain of CNY 3,899,115.34 in the same period last year[22] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 53.05%, amounting to ¥25,813,931.15 compared to ¥54,977,540.05 in the same period last year[4] - The company's cash and cash equivalents decreased to CNY 117,268,682.42 from CNY 149,316,999.85, reflecting a decline of approximately 21.5%[15] - The ending balance of cash and cash equivalents was 103,037,097.49 CNY, down from 135,223,408.72 CNY at the beginning of the period, indicating a decrease in liquidity[23] - The company received 12,800,000.00 CNY in cash from borrowings, a decrease from 42,950,000.00 CNY in the previous period, suggesting tighter credit conditions[23] - Cash outflow for repaying debts was 10,370,000.00 CNY, compared to 28,441,661.27 CNY in the previous period, indicating a reduction in debt repayment obligations[23] - The company distributed dividends and interest payments totaling 38,492,874.71 CNY, down from 44,261,720.18 CNY in the previous period, reflecting a potential strategy to conserve cash[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,240,218,479.11, a slight decrease of 0.49% from ¥8,280,629,979.39 at the end of the previous year[4] - The equity attributable to shareholders decreased by 1.85%, amounting to ¥1,889,045,772.00 compared to ¥1,924,701,823.57 at the end of the previous year[4] - The company's total liabilities decreased slightly to CNY 5,955,206,531.83 from CNY 5,967,412,152.41[21] - The total current liabilities decreased to CNY 5,152,530,199.12 from CNY 5,161,681,554.89, showing a reduction of about 0.2%[17] Operational Challenges - The company is facing liquidity issues, leading to disputes over loan contracts and the freezing of 110,422,897 shares, which represents 16.70% of the total share capital[13] - The company has initiated debt restructuring strategies, including asset sales and bank loan extensions, to optimize its debt structure[14] - The company is actively seeking support from local government and regulatory bodies to facilitate debt restructuring and financial assistance[14] Other Financial Metrics - Total operating revenue for Q1 2024 was CNY 568,856,745.84, a decrease of 3.0% from CNY 588,724,855.57 in the previous year[19] - Total operating costs increased to CNY 591,588,915.65, up 0.1% from CNY 587,997,301.38[19] - Research and development expenses for Q1 2024 were CNY 17,327,643.17, slightly down from CNY 17,941,867.46[19] - The company reported a cash flow impact from exchange rate changes of 46.22 CNY, contrasting with -54,629.23 CNY in the previous period, suggesting a stabilization in foreign exchange effects[23] - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[24]